ClinicalTrials.gg

Program

GS-3242

A development code. Also written as “GS-3242 Tablet” and “GS-3242 Injection”.

Its studies are led by Gilead Sciences.

Furthest: phase 3, since Jul 13, 20264 company-led studies, 3 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences43 open or runningphase 3since Jul 13, 2026May 23, 2025Aug 2027phase 2 · NCT07645287

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 23, 2025First study: phase 1 study in HIV-1-infectionFirst studyNCT07001319 · 27 enrolled · United States, Mexico, Thailand
  2. Jun 8, 2026Phase 2 study in HIV-1-infectionNCT07645287 · 175 planned · United States, Australia, Canada and more
  3. Jul 13, 2026Phase 3 study in HIV-1-infectionPhase 3 reachedNCT07708727 · 700 planned · United States, Canada, Germany and more
  4. Sep 21, 2026Phase 2 study in HIV-1 InfectionNCT07841990 · 125 planned · United States

Ahead

  1. Aug 2027Primary completion: phase 2 study in HIV-1 InfectionNCT07841990
  2. Aug 2027Primary completion: phase 2 study in HIV-1-infectionNCT07645287
  3. Oct 2030Primary completion: phase 3 study in HIV-1-infectionNCT07708727

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07841990HIV-1 Infection · United States2RecruitingAug 2027125
NCT07708727HIV-1-infection · United States, Canada, Germany and more3RecruitingOct 2030700
NCT07645287HIV-1-infection · United States, Australia, Canada and more2RecruitingAug 2027175
NCT07001319HIV-1-infection · United States, Mexico, Thailand1CompletedMar 3, 202627

How it is read

Names in the registry

  • “GS-3242 Tablet”, 2 entries
  • “GS-3242 Injection”, 2 entries
  • “GS-3242”, 2 entries

Codes read as this program: GS3242.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.